Noticias y vídeos - ALLIANCE PHARMA ORD 1P

Pioneering Health & Wellness Brand Amberen® Launches New Dietary Supplement Designed to Relieve the Most Common Early Perimenopausal Symptoms PR Newswire RALEIGH, N.C., May 30, 2024 New Amberen ENERGY MOOD SLEEP Gummies fight the symptom cycle by targeting low energy & mood swings, and helping to improve sleep RALEIGH, N.C. , May 30, 2024 /PRNewswire/ -- Amberen ® , a leading brand in symptom relief innovation supporting all phases of menopause, announced today the launch of Amberen ENERGY...

Alliance Pharma, un chef de file mondial des services bioanalytiques, du DMPK et des tests CFC dans le secteur pharmaceutique et biopharmaceutique, et Drug Development Solutions, Ltd. ( acquis en 2022 ), annoncent aujourd'hui qu'ils évolueront sous la nouvelle dénomination Resolian , intégrant pleinement les deux entreprises dans une seule entité. Cette opération rassemble les laboratoires bioanalytiques et les experts des entreprises aux États-Unis, au Royaume-Uni, et plus récemment en...

Ampersand-backed Alliance Pharma to acquire LGC's Drug Development Solutions Business ("DDS") and welcomes KKR as joint shareholder PR Newswire MALVERN, Pa. and CAMBRIDGE, United Kingdom and SANDWICH, United Kingdom, May 17, 2022 MALVERN, Pa. and CAMBRIDGE, United Kingdom and SANDWICH, United Kingdom , May 17, 2022 /PRNewswire/ -- Alliance Pharma, a US-based Bioanalytical CRO and an Ampersand portfolio company, has agreed to acquire DDS, a UK-based Bioanalytical Business Unit of LGC. KKR will...

Ampersand-backed Alliance Pharma to acquire LGC's Drug Development Solutions Business ("DDS") and welcomes KKR as joint shareholder PR Newswire MALVERN, Pa. and CAMBRIDGE, United Kingdom and SANDWICH, United Kingdom, May 17, 2022 MALVERN, Pa. and CAMBRIDGE, United Kingdom and SANDWICH, United Kingdom , May 17, 2022 /PRNewswire/ -- Alliance Pharma, a US-based Bioanalytical CRO and an Ampersand portfolio company, has agreed to acquire DDS, a UK-based Bioanalytical Business Unit of LGC. KKR will...

Hardman & Co Research Hardman & Co Research: Alliance Pharma (APH): International brands driving performance 07-Nov-2018 / 13:35 GMT/BST Hardman & Co: International brands driving performance Alliance Pharma (APH) is a profitable, cash-generative, specialty pharma business. The proportion of sales generated from higher margin international star brands is rising rapidly, and will be boosted by the recent acquisition of Nizoral in APAC, and UK approval and launch of Xonvea for nausea and vomiting...

Hardman & Co Research Hardman & Co Research: Alliance Pharma (APH): 2018: a year of international progress 01-Aug-2018 / 09:56 GMT/BST Hardman & Co: 2018: a year of international progress Alliance Pharma (APH) is continuing with its buy-and-build strategy, having evolved through 35 acquisitions over a period of 20 years into a profitable, cash-generative, specialty pharma business. The company has a mix of international growth brands - Kelo-cote, MacuShield, Vamousse - and a bedrock of solid,...

Hardman & Co Research Hardman & Co Research: Alliance Pharma (APH): Entering the US market 19-Apr-2018 / 07:15 GMT/BST Hardman & Co Research: Entering the US market Alliance Pharma (APH) is continuing with its buy-and-build strategy having evolved through 35 acquisitions over a period of 20 years into a profitable, cash-generative, specialty pharma business. The company has a mix of international growth brands -Kelo-cote and MacuShield - and a bedrock of solid local low-growth products....

VIDEO FINANCIAL REPORTING Why invest in is the first financial video platform where you can easily search through thousands of videos describing global ......

...